Trial Profile
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2020
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- 24 Jun 2020 Results assessing biomarkers prognostic of clinical response to regorafenib in patients with metastatic colorectal cancer, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 09 Aug 2018 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.
- 09 Aug 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Oct 2018.